---
document_datetime: 2024-09-25 09:40:17
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ucedane-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: ucedane-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.408734
conversion_datetime: 2025-12-31 04:50:05.996113
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ucedane

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0017               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 24/09/2024                          |                                             | PL                               |           |
| IB/0016/G            | This was an application for a group of variations.                                               | 08/07/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition   |            |            |                           |                                                                                                                                                                             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0015 | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/04/2024 | n/a        |                           |                                                                                                                                                                             |
| IB/0014 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                               | 19/01/2024 |            | SmPC, Annex II and PL     |                                                                                                                                                                             |
| IA/0013 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 05/07/2022 | 09/10/2023 | SmPC, Annex II and PL     |                                                                                                                                                                             |
| R/0011  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 27/01/2022 | 28/03/2022 | SmPC, Annex II, Labelling | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ucedane in the approved indication remains favourable and |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                              |            |            | and PL          | therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                         |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0012    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 10/12/2021 | 28/03/2022 | PL              |                                                                                                                                                                                                                                                                   |
| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 16/06/2021 | 28/03/2022 | SmPC and PL     | To extend the indications of medicinal product for hyperammonaemia due to isovaleric acidaemia, hyperammonaemia due to methylmalonic acidaemia, and hyperammonaemia due to propionic acidaemia following assessment of the same change for the reference product. |
| IA/0010   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                               | 11/06/2021 | n/a        |                 |                                                                                                                                                                                                                                                                   |
| N/0007    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 28/09/2020 | 28/03/2022 | PL              |                                                                                                                                                                                                                                                                   |
| IAIN/0006 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                           | 30/06/2020 | n/a        |                 |                                                                                                                                                                                                                                                                   |
| N/0005    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 30/08/2019 | 04/02/2020 | PL              |                                                                                                                                                                                                                                                                   |
| IG/1105/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                        | 06/06/2019 | 04/02/2020 | Annex II and PL |                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0002/G | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.a.1.b - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in scoring/break lines intended to divide into equal doses B.II.a.2.b - Change in the shape or dimensions of the pharmaceutical form - Gastro-resistant, modified or prolonged release pharmaceutical forms and scored tablets intended to be divided into equal doses B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.e - Change to in-process tests or limits applied during the manufacture of the finished product - Widening of the approved IPC limits, which may have a significant effect on overall quality of the finished product B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change | 31/01/2019 | 04/02/2020 | SmPC and PL | As a result of this group of variation and implementation of score lines for dosing increments of 50 mg, the SmPC have been updated as follows: 3. PHARMACEUTICAL FORM Dispersible tablet. The tablets are white, oval and biconvex with one score line and engraving LL. The tablets are rod-shaped, white and biconvex with three score lines on both sides and engraving 'L/L/L/L' on one side. The tablet can be divided into four equal doses. 4.2 Posology and method of administration The breaking of the tablets in halves allows most of the required posology adjustments. Occasionally, the use of quarter tablets may also be useful to adjust the posology prescribed by the physician. It is not possible to administer Ucedane to patients who require dose adjustments of 50 mg. In such cases, other carglumic acid products which allow for these dose adjustments should be used. The PL have been updated accordingly. |

<div style=\"page-break-after: always\"></div>

|         | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0003  | Transfer of Marketing Authorisation                                                                                                                                                                                                                            | 12/10/2018 | 07/12/2018 | SmPC, Labelling and PL |
| IB/0001 | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                            | 19/07/2017 | 30/07/2018 | SmPC, Labelling and PL |